Alterations in serum amino acid concentrations in male and female schizophrenic patients

Clinica Chimica Acta

Volumn 380, Issue 1-2, 2007, Pages 186-190

  Tomiya, Masayuki ^a   Fukushima, Takeshi ^a   Watanabe, Hiroyuki ^b   Fukami, Goro ^b   Fujisaki, Mihisa ^b   Iyo, Masaomi ^b   Hashimoto, Kenji ^b   Mitsuhashi, Shogo ^a   Toyo'oka, Toshimasa ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

4 fluoro 7 nitro 2,1,3 benzoxadiazole; Glutamate; Human serum; Proline; Schizophrenia; Serine

Indexed keywords

4 FLUORO 7 NITRO 2,1,3 BENZOXADIAZOLE; AMINO ACID; BENZOXAZOLE DERIVATIVE; CHLORPROMAZINE; GLUTAMIC ACID; PROLINE; SERINE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DISEASE DURATION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DISEASE; ONSET AGE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SERUM; SEX DIFFERENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHLORPROMAZINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; PIPERAZINES; SCHIZOPHRENIA; SEX FACTORS;

EID: 33947724645     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.02.011     Document Type: Article

References (28)

1. Aleman A., Kahn R.S., and Selten J.P. Sex differences in the risk of schizophrenia. Arch Gen Psychiatry 60 (2003) 565-571
2. Grossman L.S., Harrow M., Rosen C., and Faull R. Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. Psychiatr Serv 57 (2006) 844-850
3. Riecher-Rossler A. Oestrogen effects in schizophrenia and their potential therapeutic implications - review. Arch Womens Ment Health 5 (2002) 111-118
4. Bergemann N., Mundt C., Parzer P., et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 73 (2005) 357-366
5. Kulkarni J., Riedel A., de Castella A.R., et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res 48 (2001) 137-144
6. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52 (1995) 998-1007
7. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158 (2001) 1367-1377
8. Hashimoto K., Shimizu E., and Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatr Rev 1 (2005) 151-163
9. van der Heijden F.M.M.A., Fekkes D., Tuinier S., Sijben A.E.S., Kahn R.S., and Verhoeven W.M.A. Amino acids in schizophrenia: evidence for lower tryptophan availability during treatment with atypical antipsychotics?. J Neural Transm 112 (2005) 577-585
10. van der Heijden F.M.M.A., Tuinier S., Fekkes D., Sijben A.E.S., Kahn R.S., and Verhoeven W.M.A. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 14 (2004) 259-265
11. Kim J.S., Kornhuber H.H., Schmid-Burgk W., and Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20 (1980) 379-382
12. Sumiyoshi T., Anil A.E., Jin D., Jayathilake K., Lee M., and Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 7 (2004) 1-8
13. Neeman G., Blanaru M., Bloch B., et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162 (2005) 1738-1740
14. Tortorella A., Monteleone P., Fabrazzo M., Viggiano A., De Luca L., and Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 44 (2001) 167-171
15. Tomiya M., Fukushima T., Kawai J., et al. Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-d-aspartate receptor antagonist, ketamine. Biomed Chromatogr 20 (2006) 628-633
16. Imai K., and Watanabe Y. Fluorimetric determination of secondary amino acids by 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole. Anal Chim Acta 130 (1981) 377-381
17. Aoyama C., Santa T., Tsunoda M., Fukushima T., Kitada C., and Imai K. A fully automated amino acid analyzer using NBD-F as a fluorescent derivatization reagent. Biomed Chromatogr 18 (2004) 630-636
18. Fekkes D., van Dalen A., Edelman M., and Voskuilen A. Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated pre-column derivatization with o-phthaldialdehyde. J Chromatogr B 669 (1995) 177-186
19. Fukushima T., Mitsuhashi S., Tomiya M., Iyo M., Hashimoto K., and Toyo'oka T. Determination of kynurenic acid in human serum and its correlation with the concentration of certain amino acids. Clin Chim Acta 377 (2007) 174-178
20. Hashimoto K., Fukushima T., Shimizu E., et al. Decreased serum levels of d-serine in patients with schizophrenia. Evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60 (2003) 572-576
21. Cohen S.M., and Nadler J.V. Proline-induced potentiation of glutamate transmission. Brain Res 761 (1997) 271-282
22. Renick S.E., Kleven D.T., Chan J., et al. The mammalian brain high-affinity l-proline transporter is enriched preferentially in synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain. J Neurosci 19 (1999) 21-33
23. Takemoto Y., and Semba R. Immunohistochemical evidence for the localization of neurons containing the putative transmitter l-proline in rat brain. Brain Res 1073-1074 (2006) 311-315
24. Tunbridge E., Burnet P.W.J., Sodhi M.S., and Harrison P.J. Catechol-O-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Synapse 51 (2004) 112-118
25. Liu H., Abecasis G.R., Heath S.C., et al. Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci U S A 99 (2002) 16859-16864
26. Paterlini M., Zakharenko S.S., Lai W.S., et al. Transcriptional and behavioural interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8 (2005) 1586-1594
27. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24 (1998) 285-301
28. Jacquet H., Raux G., Thibaut F., et al. PRODH mutations and hyperprolinaemia in a subset of schizophrenic patients. Hum Mol Genet 11 (2002) 2243-2249